Alnylam scolded over promotional activity after Pfizer complaint
Alnylam Pharmaceuticals faces regulatory scrutiny over promotional practices following a complaint by Pfizer.
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (NASDAQ: ALNY) is the leading RNAi therapeutics company, with six approved products (Onpattro, Givlaari, Oxlumo, Amvuttra, Qfitlia, and the Leqvio collaboration with Novartis) and a deep pipeline in cardiometabolic, hepatic infectious disease, and CNS indications. Alnylam's approved medicines target transthyretin amyloidosis (Onpattro, Amvuttra), acute hepatic porphyria (Givlaari), primary hyperoxaluria type 1 (Oxlumo), and hemophilia A and B (Qfitlia). Leqvio (inclisiran), licensed to and commercialized by Novartis, targets LDL cholesterol.
Company Info
Sector:RNA Therapeutics
Headquarters:Cambridge, Massachusetts, USA
Founded:2002
Website:www.alnylam.com/
Recent News
Alnylam scolded over promotional activity after Pfizer complaint
Alnylam drew regulatory scrutiny over its promotional activity after a complaint from Pfizer, highlighting ongoing tension between innovators and generic / biosimilar competitors.
Leadership Team
Yvonne Greenstreet
Chief Executive Officer
Careers & Job Openings